MDGN201 TARGTEPO

BIOLOGICAL3 trials

Sponsors

Aevi Genomic Medicine, LLC, a Cerecor company

Conditions

Anemia of End Stage Renal DiseaseChronic Kidney DiseaseEnd Stage Renal Disease

Phase 1

TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)

CompletedNCT02117427

Aevi Genomic Medicine, LLC, a Cerecor companyChronic Kidney Disease, End Stage Renal Disease

Start: 2014-05-27End: 2017-03-20Updated: 2018-10-30

Phase 2

TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)

TerminatedNCT02378662

Aevi Genomic Medicine, LLC, a Cerecor companyAnemia of End Stage Renal Disease

Start: 2015-04-30End: 2016-06-30Updated: 2018-10-19

TARGTEPO Treatment for Anemia in PD US Trial

TerminatedNCT02468414

Aevi Genomic Medicine, LLC, a Cerecor companyAnemia of End Stage Renal Disease

Start: 2015-06-30End: 2016-09-30Updated: 2022-03-28